MAXCYTE, INC. - Common Stock (MXCT)

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Equity / Common Stock
Shares outstanding
106,493,506
Total 13F shares
67,408,377
Share change
-774,123
Total reported value
$367,290,212
Put/Call ratio
20%
Price per share
$5.46
Number of holders
98
Value change
-$4,673,528
Number of buys
49
Number of sells
39

Institutional Holders of MAXCYTE, INC. - Common Stock (MXCT) as of Q4 2022

As of 31 Dec 2022, MAXCYTE, INC. - Common Stock (MXCT) was held by 98 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 67,408,377 shares. The largest 10 holders included Casdin Capital, LLC, BlackRock Inc., Vitruvian Partners LLP, VANGUARD GROUP INC, Blue Water Life Science Advisors, LP, Holocene Advisors, LP, ArrowMark Colorado Holdings LLC, BAMCO INC /NY/, CITADEL ADVISORS LLC, and MASSACHUSETTS FINANCIAL SERVICES CO /MA/. This page lists 100 institutional shareholders reporting positions in this security for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.